![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Calyptus Wins FDA Approval for Bovana Generic
Calyptus Wins FDA Approval for Bovana Generic
Calyptus Pharmaceuticals has secured FDA approval for its generic version of Sunovion Pharmaceuticals’ Brovana (arformoterol tartrate inhalation solution) as a maintenance treatment for bronchoconstriction in patients with obstructive pulmonary disease (COPD).
Calyptus, which co-developed the drug with VistaPharm, noted that the long-term, twice daily inhalation therapy may be used by patients with chronic bronchitis and emphysema.
U.S. sales of arformoterol tartrate inhalation solution, reached an estimated $104 million for the 12-month period ending June 2022, according to the healthcare analytics firm IQVIA.
Upcoming Events
-
18Jul
-
21Oct